Q2 revenue of $95.6M exceeds FactSet estimate; U.S. market remains resilient.
InMode reported Q2 2026 revenue of $95.6 million, beating the FactSet consensus estimate of $93.1 million. The beat reflects steady U.S. demand for its RF microneedling and energy-based platforms, signaling continued patient appetite for minimally invasive aesthetic procedures.
For medspa owners, InMode's beat matters because it validates the RF microneedling market and suggests device utilization remains strong. InMode's installed base is substantial, and a beat signals that practices are running treatments and generating revenue per device. If you own an InMode platform (Morpheus8, Secret RF), the earnings confirm the market is absorbing supply.
Q2 revenue of $95.6M exceeds FactSet estimate; U.S. market remains resilient.
However, context matters: InMode's Q2 also showed flat revenue and margin compression in other segments. The U.S. device market is competitive, and pricing pressure is real. Before upgrading or adding a second RF microneedling device, confirm your current device's utilization rate and per-treatment margin. A beat does not guarantee your practice's ROI on new capital.
Source: original report ↗
Frequently asked questions
Is RF microneedling device demand actually growing in 2026?
InMode's Q2 2026 revenue of $95.6M beat analyst estimates by $2.5M, driven by steady U.S. device demand for RF microneedling platforms like Morpheus8 and Secret RF. This signals continued patient appetite for minimally invasive aesthetic procedures and strong device utilization among existing practices.
Should I buy a second RF microneedling device based on InMode's earnings beat?
Not automatically. While InMode's beat validates the RF microneedling market, the company also reported flat revenue and margin compression in other segments. Before investing in a second device, audit your current device's utilization rate and per-treatment margin to ensure ROI on new capital.
What does InMode's Q2 beat tell me about my Morpheus8 or Secret RF device?
InMode's beat indicates the market is absorbing supply and practices are running treatments profitably. Your device's strong performance in a beat quarter suggests the broader market remains resilient, but your own ROI depends on your specific utilization and pricing—not InMode's overall results.
Is there pricing pressure on RF microneedling devices right now?
Yes. While InMode beat revenue estimates, the U.S. device market is competitive and pricing pressure is real, as evidenced by margin compression in other segments. Confirm your per-treatment margins and competitive positioning before committing to additional capital expenditure.
How do I know if my RF microneedling device is performing well enough to justify expansion?
Calculate your current device's utilization rate (treatments per week) and per-treatment margin (revenue minus cost of goods and labor). Compare these metrics to your target ROI timeline for a new device purchase; InMode's beat validates market demand but doesn't replace your own operational metrics.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
